

Warum reagiert mein Patient anders auf dieses Medikament? Pharmakogenomik und Personalisierte Medizin in der Praxis.

Objectifs et bénéfices de l'évaluation en milieu de travail dans la pratique clinique quotidienne

Literatur / Références

- 1 Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. *Trends Mol Med.* 2001;7(5):201–4.
- 2 Meyer UA Genes and the individual response to treatment. In: *Treating Individuals: From randomised trials to personalised medicine (Lancet Handbook)*(Rothwell, P. M., ed), pp 151–68: Elsevier; 2007.
- 3 Roots I, Laschinski G, Meyer UA Pharmakogenetik und Pharmakogenomik. In: *Grundlagen der Molekularen Medizin*(Ganten and Ruckpaul, eds), pp 314–31: Springer; 2008.
- 4 Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. *Pharmacol Rev.* 2011;63(2):437–59.
- 5 Meyer UA. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. *Nat Rev Genet.* 2004;5(9):669–76.
- 6 Meyer UA. Endo-xenobiotic crosstalk and the regulation of cytochromes P450. *Drug Metab Rev.* 2007;39(2–3):639–46.
- 7 Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. *N Engl J Med.* 2011;365(21):2002–12.
- 8 1000 Genomes Project Consortium NN. A map of human genome variation from population-scale sequencing. *Nature.* 2010;467(7319):1061–73.
- 9 Daly AK. Pharmacogenetics and human genetic polymorphisms. *Biochem J.* 2010;429(3):435–49.
- 10 Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *N Engl J Med.* 2004;351(27):2827–31.
- 11 Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. *Clin Pharmacol Ther.* 2012;91(2):321–6.
- 12 Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. *Pharmacol Rev.* 2011;63(1):157–81.
- 13 Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. *Clin Cancer Res.* 2010;16(1):291–303.
- 14 Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. *Pharmacol Rev.* 2003;55(4):649–73.
- 15 Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. *Lancet.* 2000;355(9203):548–9.
- 16 Pene F, Courtine E, Cariou A, Mira JP. Toward theragnostics. *Crit Care Med.* 2009;37(1 Suppl):S50–8.
- 17 Meyer UA. Personalized medicine: a personal view. *Clin Pharmacol Ther.* 2012;91(3):373–5.
- 18 Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. *Trends Pharmacol Sci.* 2004;25(4):193–200.
- 19 Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med.* 2011;364(26):2507–16.
- 20 Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med.* 2008;358(6):568–79.
- 21 Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. *EMBO Mol Med.* 2010;2(5):146–58.
- 22 Hewitt RE. Biobanking: the foundation of personalized medicine. *Curr Opin Oncol.* 2011;23(1):112–9.
- 23 Moch H, Blank PR, Dietel M, Elmberger G, Kerr KM, Palacios J, et al. Personalized cancer medicine and the future of pathology. *Virchows Arch.* 2012;460(1):3–8.
- 24 Deverka PA, Vernon J, McLeod HL. Economic opportunities and challenges for pharmacogenomics. *Annu Rev Pharmacol Toxicol.* 2010;50(423–37).
- 25 Payne K, Shabaruddin FH. Cost-effectiveness analysis in pharmacogenomics. *Pharmacogenomics.* 2010;11(5):643–6.

- 26 Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. *Pharmacoeconomics*. 2010;28(11):1001–13.
- 27 Bates S. Progress towards personalized medicine. *Drug Discov Today*. 2010;15(3–4):115–20.
- 28 Li C. Personalized medicine – the promised land: are we there yet? *Clin Genet*. 2011;79(5):403–12.
- 29 Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. *Pharmacogenet Genomics*. 2011;21(12):837–50.
- 30 Drazen JM. A step toward personalized asthma treatment. *N Engl J Med*. 2011;365(13):1245–6.
- 31 Kahn SD. On the future of genomic data. *Science*. 2011;331(6018):728–9.
- 32 Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HYK, Chen R, et al. Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes. *Cell*. 2012;148(6):1293–307.
- 33 Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther*. 2011;89(3):387–91.
- 34 Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. *N Engl J Med*. 2011;364(12):1126–33.
- 35 McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. *N Engl J Med*. 2011;364(12):1134–43.
- 36 Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450–2C19 (CYP2C19) genotype and clopidogrel therapy. *Clin Pharmacol Ther*. 2011;90(2):328–32.
- 37 Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. *J Clin Oncol*. 2004;22(8):1382–8.
- 38 European Association for the Study of the Liver NN. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol*. 2011;55(2):245–64.
- 39 Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. *Gastroenterology*. 2011;140(3):1021–31.
- 40 Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. *Drug Saf*. 2010;33(9):713–26.
- 41 de Souza JA, Olopade OI. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. *Semin Oncol*. 2011;38(2):263–73.
- 42 Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. *Clin Pharmacol Ther*. 2011;90(4):625–9.
- 43 Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, van der Meer FJ, le Cessie S, et al. Long-term anticoagulant effects of CYP2C9 and VKORC1 genotype in acenocoumarol users. *J Thromb Haemost*. 2012.
- 44 Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M, et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. *Eur J Clin Pharmacol*. 2010;66(3):253–60.
- 45 Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. *Clin Pharmacol Ther*. 2005;77(6):479–85.